WOODBRIDGE, Ontario,
September 3, 2014 /PRNewswire/ --
Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO),
("Pivotal" or the "Company"), a specialty pharmaceutical company
with a focus on Omega-3 therapies for cardiovascular disease
("CVD") and overall health, announced today that the
cardio-protective effects of Pivotal's unique Omega-3 formulation
commercialized as VASCAZEN® was presented
at the 2014 Annual Scientific Meeting of the European Society of
Cardiology ("ESC") Congress 2014 in Barcelona, Spain, by Rasul et al. from the
Laboratory of Biophotonics and Pharmacology of the University of
Strasbourg, France.
The presented poster, entitled "Chronic oral intake of the
omega 3 optimized formulation EPA:DHA 6:1 protects against
angiotensin II-induced hypertension and endothelial dysfunction in
rats," indicated that chronic intake of
VASCAZEN®'s EPA:DHA 6:1 prevented the
development of hypertension and endothelial dysfunction in a rodent
model. The vasoprotective and antihypertensive effects of
VASCAZEN® is mediated by an improvement of
both the nitric oxide (NO) and the EDH-mediated relaxations as well
as a reduction of endothelium-dependent contractile response.
"These findings show that formulation, purity and dose plays a
significant role in biological activity," said Dr. George Jackowski, Chief Scientific Officer.
"Until now, many Cardiologists believed that all Omega-3s had
similar vasodilatory effects, regardless of formulation. We are
very pleased to have had this opportunity to educate the attendees
of the ESC Congress about the unique
VASCAZEN® EPA:DHA 6:1 formulation and its
proven clinical superiority over other existing commercial products
in the marketplace in terms of sustained coronary vasodilation
(i.e. increase of blood flow)."
About Pivotal Therapeutics Inc.
Pivotal Therapeutics is a publicly traded (OTCQX:PVTTF;
CSE:PVO), specialty pharmaceutical company with a focus on
cardiovascular disease and overall health. Pivotal Therapeutics'
lead product VASCAZEN® is a prescription
only medical food formulated to meet the dietary Omega-3 deficient
needs of patients with cardiovascular disease through elevating
Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to
levels associated with reduced risk of cardiovascular
complications. OMAZEN®is a pharmaceutical
grade Omega-3 providing over 90% pure Omega-3 in each capsule for
the maintenance of good health. OMAZEN® is
a patented product available for sale and distribution in
Canada.
About VASCAZEN®
VASCAZEN® is currently available in the
U.S. as a prescription only medical food specifically formulated
for the dietary management of an Omega-3 deficiency in
cardiovascular patients. VASCAZEN® is a
>90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid
formulation, protected by a series of both U.S. and foreign
patents.
VASCAZEN® has been clinically shown to
correct an Omega-3 deficiency within eight weeks of treatment with
positive concomitant effects on the lipid profiles, mainly a 48%
reduction of triglycerides and an increase of HDL without negative
impact on the LDL-C lipid profile.
VASCAZEN®'s results were achieved with a
dose of 3 grams of EPA and DHA per day of a prescription grade,
high purity, uniquely formulated Omega-3.
Disclosure Notice
The information contained in this document is as of
September 3, 2014. This press release
contains forward-looking statements. Such forward-looking
statements are subject to a number of risks, assumptions and
uncertainties that could cause Pivotal's actual results to differ
materially from those projected in such forward-looking statements.
These statements can be identified by the use of words such as
"will", "anticipate", "estimate", "expect", "project", "forecast",
"intend", "plan", "believe", "project", "potential", and similar
expressions with any discussion of future operating or financial
performance or events. In particular, factors that could cause
actual results to differ materially from those in forward looking
statements include the following: Pivotal's inability to obtain
additional financing on acceptable terms; growth in costs and
expenses; inability to compete with others who provide comparable
products; risk that the Company's products will not gain widespread
market acceptance; risks relating to the Company's ability to
maintain its CSE listing. Forward-looking statements speak only as
of the date made and are not guarantees of future performance. The
Company undertakes no obligation to publicly update or revise any
forward-looking statements contained in this document as a result
of new information or future events or developments. The CSE has
not reviewed and does not accept responsibility for the adequacy or
accuracy of this information.
For further information:
Company Contacts:
Kristine DiMatteo
Communications and Public Relations Manager
Phone: +1-905-856-9797 ext. 231
E-Mail: kdimatteo@pivotaltherapeutics.us
Investor & Media Contact:
Stephen Kilmer
President, Kilmer Lucas Inc.
Phone: +1-647-872-4849
E-Mail: stephen@kilmerlucas.com